Sodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar rats

Biomed Pharmacother. 2021 Jan:133:110994. doi: 10.1016/j.biopha.2020.110994. Epub 2020 Nov 13.

Abstract

High fat diet (HFD) is a risk factor for metabolic syndrome which is characterized by overt glucose dysmetabolism and tissue derangement. The liver and pancreas are important metabolic tissues with anatomical proximity sharing splanchnic and mesenteric circulation but it is unclear whether, there is an associated metabolic status between the two organs in health and disease. Uric acid (UA) hypersecretion and ectopic lipid accumulation are characteristic pathophysiology of an array of non-communicable diseases. Sodium butyrate (BUT) is reputed for therapeutic roles in metabolic derangement. Therefore, the present study investigated synchrony in hepatic and pancreatic UA and lipid metabolic status in HFD-induced glucose dysregulation and probed the beneficial effects of BUT. Twenty-four female Wistar rats were treated with normal rat chow and distilled water (po) or sodium butyrate (200 mg/kg; po) or high fat diet and distilled water (po) or high fat diet and sodium butyrate. Results showed that HFD increased plasma, pancreatic and hepatic triglyceride, triglyceride-glucose index, malondialdehyde, uric acid (UA), lactate dehydrogenase but reduced glucose-6-phosphate dehydrogenase. Histological analysis revealed hepatic and pancreatic architectural derangement and cellular degeneration in HFD-fed animals. However, BUT reversed the HFD-induced systemic, pancreatic and hepatic synchronous dysmetabolism with evidence of improved histology. HFD-induced lipid and UA alterations were synchronous in the pancreas and liver. BUT elicits beneficial effects on systemic and tissue HFD-induced deleterious metabolic changes which were synchronized in pancreas and liver of rats.

Keywords: High fat diet; NAFLD; Pancreas; Short chain fatty acids; Uric acid.

MeSH terms

  • Animals
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Butyric Acid / pharmacology*
  • Diet, High-Fat
  • Disease Models, Animal
  • Dyslipidemias / blood
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / etiology
  • Dyslipidemias / pathology
  • Female
  • Glucose Metabolism Disorders / blood
  • Glucose Metabolism Disorders / drug therapy
  • Glucose Metabolism Disorders / etiology
  • Hyperuricemia / blood
  • Hyperuricemia / drug therapy*
  • Hyperuricemia / etiology
  • Hyperuricemia / pathology
  • Hypoglycemic Agents / pharmacology
  • Hypolipidemic Agents / pharmacology*
  • Lipids / blood*
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / pathology
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / pathology
  • Pancreas / drug effects*
  • Pancreas / metabolism
  • Pancreas / pathology
  • Rats
  • Rats, Wistar
  • Uric Acid / blood*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Lipids
  • Butyric Acid
  • Uric Acid